Active MMPs captured by alpha2Macroglobulin as a marker of disease activity in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 21, Issue 6, 2003, Pages 711-718

  Tchetverikov, I ^a,b   Verzijl, N ^a   Huizinga, T W J ^b   TeKoppele, J M ^a   Hanemaaijer, R ^a   DeGroot, Jeroen ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

2Macroglobulin; Matrix metalloproteases; Rheumatoid arthritis

Indexed keywords

ALPHA 2 MACROGLOBULIN; BATIMASTAT; COLLAGENASE 3; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CIRCULATION; CLINICAL ARTICLE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FAST PROTEIN LIQUID CHROMATOGRAPHY; FLUORESCENCE ANALYSIS; HUMAN; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS;

ADULT; ALPHA-MACROGLOBULINS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROBABILITY; PROGNOSIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0346258210     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. NAGASE H, WOESSNER JFJ: Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
2. NAGASE H, OKADA Y: Proteinases and matrix degradation. In KELLEY WN, HARRIS ED, RUDDY S and SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders, 1998: 323-41.
3. BRESNIHAN B: Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26: 717-9.
4. MURPHY G, KNAUPER V, ATKINSON S et al.: Matrix metalloproteinases in arthritic disease. Arthritis Res 2002; 4 (Suppl. 3): S39-49.
5. KONTTINEN YT, AINOLA M, VALLEALA H et al.: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58: 691-7.
6. YAMANAKA H, MATSUDA Y, TANAKA M et al.: Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000; 43: 852-8.
7. POSTHUMUS MD, LIMBURG PC, WESTRA J et al.: Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 2000; 27: 2761-8.
8. MARTEL-PELLETIER J, MCCOLLUM R, FUJIMOTO N et al.: Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807-15.
9. BURGER D, REZZONICO R, LI JM et al.: Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines. Arthritis Rheum 1998; 41: 1748-59.
10. VAN DER LAAN WH, GOOSSENS PH, PIETERMAN EJ et al.: More profound inhibitory effect of TIMP-3 gene transfer than TIMP-1 gene transfer on synovial fibroblast invasion. Arthritis Rheum 2000; 43, 9 (Suppl.): S170.
11. YOSHIHARA Y, NAKAMURA H, OBATA K et al.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59: 455-61.
12. MOESTRUP SK, HOLTET TL, ETZERODT M et al.: Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats. J Biol Chem 1993; 268: 13691-6.
13. GRINNELL F, ZHU M, PARKS WC: Collagenase-1 complexes with alpha2-macroglobulin in the acute and chronic wound environments. J Invest Dermatol 1998; 110: 771-6.
14. EKEROT L, OHLSSON K: Protease inhibitors in rheumatoid synovial fluid. Analyses of electrophoretic homogeneity and protease inhibitory capacity. Rheumatol Int 1982; 2: 21-6.
15. BEEKMAN B, DRIJFHOUT JW, RONDAY HK et al.: Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. Ann NY Acad Sci 1999; 878: 150-8.
16. BEEKMAN B, DRIJFHOUT JW, BLOEMHOFF W et al.: Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett 1996; 390: 221-5.
17. DRIJFHOUT JW, NAGEL JBB, TEKOPPELE JM, BLOEMHOFF W: Solid phase synthesis of peptides containing the fluorescence energy transfer Dabcyl-EDANS coupe. In KAUMAYA PTP and HODGES RS (Eds.): Peptides, Chemistry, Structure and Biology. Mayflower Scientic Ltd., 1996: 129-31.
18. MURPHY G, WILLENBROCK F: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510.
19. DEGROOT J, VERZIJL N, WENTING-VAN WIJK MJ et al.: Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum 2001; 44: 2562-71.
20. HANEMAAIJER R, VISSER H, KONTTINEN YT et al.: A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 1998; 17: 657-65.
21. LARD LR, BOERS M, VERHOEVEN A et al.: Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002; 46: 899-905.
22. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23. BARRETT AJ: Alpha 2-macroglobulin. Methods Enzymol 1981; 80 Pt C: 737-54.
24. WU SM, PIZZO SV: Mechanism of hypochlorite-mediated inactivation of proteinase inhibition by alpha 2-macroglobulin. Biochemistry 1999; 38: 13983-90.
25. VERHEIJEN JH, NIEUWENBROEK NM, BEEKMAN B et al.: Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997; 323: 603-9.
26. DEAGE V, BURGER D, DAYER JM: Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1 beta and metalloproteinases. Eur Cytokine Netw 1998; 9: 663-8.
27. MANICOURT DH, FUJIMOTO N, OBATA K et al.: Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995; 38: 1031-9.
28. CHEUNG NT, MATTEY DL, DAWES PT et al.: Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: A reflection of local or systemic inflammation ? Arthritis Rheum 1996; 39: 884-6.
29. GOLDBACH-MANSKY R, LEE JM, HOXWORTH JM et al.: Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res 2000; 2: 145-53.
30. CUNNANE G, FITZGERALD O, BEETON C et al.: Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2263-74.